A Study to Determine the Safety and Sensitizing Potential of HAT1 Topical Products Using Skin Sensitivity Patch Tests

计划入组 182 人 · 首次发布于 2018 年 1 月 23 日

Efficacy and Safety of HAT1 Compared to Calcipotriol in Patients With Mild to Moderate Chronic Plaque Psoriasis

计划入组 174 人 · 首次发布于 2019 年 2 月 21 日

A Study to Evaluate the Safety and Efficacy of HAE1 in Subjects With Moderate to Severe Allergic Asthma

计划入组 50 人 · 首次发布于 2006 年 12 月 4 日

HAT1(Epizyme)

HAO-472

HAC1 Vaccine(WRAIR)

FDA Clears IND for Arbor Biotechnologies' ABO-101 Gene-Editing Therapy for Primary Hyperoxaluria Type 1

YolTech's YOLT-203 Shows Promise in Primary Hyperoxaluria Type 1 with Positive Clinical Data

ABO-101 Gene Editing Therapy for Primary Hyperoxaluria Type 1 Granted Orphan Drug Designation by European Commission